Carbamic acid,N-[2-[[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl]-3-methylphenyl]-,methyl ester

Pumaprazole has been abandoned in favor of a pharmacologically better follow up compound presently under development at Byk Gulden. The WHO decided to label the APAs by the stem syllable “-prazole” in order “to maintain the number of stems at a manageable level”, irrespective of the completely different (i.e., reversible vs. covalent) modes of drug – target interactions by APAs and PPIs (WHO decision communicated on Nov. 30, 1995). Unfortunately, this pharmacologically misleading but legally binding decision will confuse the rational use and differential perception of APAs vs. PPIs in the future and counteracts the effort for an unambiguous terminology in pharmacology. It should be noted that the terms APAs and PPIs have been coined specifically to make a clearly recognizable distinction between the two chemically and mechanistically different classes of drugs.